BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32726613)

  • 1. Platelet factor 4 regulates T cell effector functions in malignant pleural effusions.
    Mulet M; Zamora C; Porcel JM; Nieto JC; Pajares V; Muñoz-Fernandez AM; Calvo N; Esquerda A; Vidal S
    Cancer Lett; 2020 Oct; 491():78-86. PubMed ID: 32726613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental supporting data on the influence of platelet-derived factors of malignant pleural effusions on T cell effector functions and their relevance in predicting prognosis of lung adenocarcinoma patients with pleural metastasis.
    Mulet M; Zamora C; Porcel JM; Nieto JC; Pajares V; Muñoz-Fernandez AM; Calvo N; Esquerda A; Vidal S
    Data Brief; 2020 Oct; 32():106266. PubMed ID: 32984462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Migrated T lymphocytes into malignant pleural effusions: an indicator of good prognosis in lung adenocarcinoma patients.
    Nieto JC; Zamora C; Porcel JM; Mulet M; Pajares V; Muñoz-Fernandez AM; Calvo N; Espinosa I; Pascual-García M; Bielsa S; Vidal S
    Sci Rep; 2019 Feb; 9(1):2996. PubMed ID: 30816121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control.
    Qian Q; Zhan P; Sun WK; Zhang Y; Song Y; Yu LK
    Neoplasma; 2012; 59(4):433-9. PubMed ID: 22489699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Value of Vascular Endothelial Growth Factor, Transforming Growth Factor-β, Interleukin-8, and the Ratio of Lactate Dehydrogenase to Adenosine Deaminase in Pleural Effusion.
    Saraya T; Ohkuma K; Watanabe T; Mikura S; Kobayashi F; Aso J; Nunokawa H; Honda K; Ogawa Y; Tamura M; Sada M; Oda M; Inoue M; Yokoyama T; Kurai D; Ishii H; Kimura H; Takizawa H
    Lung; 2018 Apr; 196(2):249-254. PubMed ID: 29353318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired T cell function in malignant pleural effusion is caused by TGF-β derived predominantly from macrophages.
    Li L; Yang L; Wang L; Wang F; Zhang Z; Li J; Yue D; Chen X; Ping Y; Huang L; Zhang B; Zhang Y
    Int J Cancer; 2016 Nov; 139(10):2261-9. PubMed ID: 27459735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treg/Th17 imbalance in malignant pleural effusion partially predicts poor prognosis.
    Yang G; Li H; Yao Y; Xu F; Bao Z; Zhou J
    Oncol Rep; 2015 Jan; 33(1):478-84. PubMed ID: 25371165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-regulation of pro-angiogenic factors and establishment of tolerance in malignant pleural effusions.
    Lieser EA; Croghan GA; Nevala WK; Bradshaw MJ; Markovic SN; Mansfield AS
    Lung Cancer; 2013 Oct; 82(1):63-8. PubMed ID: 23948549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Malignant Pleural Fluid from Lung Adenocarcinoma Patients on Neutrophil Response.
    Mulet M; Osuna-Gómez R; Zamora C; Porcel JM; Nieto JC; Perea L; Pajares V; Muñoz-Fernandez AM; Calvo N; Sorolla MA; Vidal S
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid.
    Scherpereel A; Grigoriu BD; Noppen M; Gey T; Chahine B; Baldacci S; Trauet J; Copin MC; Dessaint JP; Porte H; Labalette M
    BMC Cancer; 2013 Jul; 13():324. PubMed ID: 23816056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor-beta 1 (TGF-beta 1)- and beta 2-like activities in malignant pleural effusions caused by malignant mesothelioma or primary lung cancer.
    Maeda J; Ueki N; Ohkawa T; Iwahashi N; Nakano T; Hada T; Higashino K
    Clin Exp Immunol; 1994 Nov; 98(2):319-22. PubMed ID: 7955539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pleural fluid osteopontin, vascular endothelial growth factor, and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion: a prospective cohort study.
    Hsu LH; Hsu PC; Liao TL; Feng AC; Chu NM; Kao SH
    BMC Cancer; 2016 Jul; 16():463. PubMed ID: 27411914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
    Tamiya M; Tamiya A; Yasue T; Nakao K; Omachi N; Shiroyama T; Tani E; Hamaguchi M; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Hirashima T
    Anticancer Res; 2016 Jun; 36(6):2939-44. PubMed ID: 27272808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine/Chemokine/Growth Factor Levels in Malignant Pleural Effusion of Non-small Cell Lung Cancer.
    Hayama N; Hattori S; Takahashi G; Takahashi F; Takeuchi T; Tanaka J; Horio Y; Takiguchi H; Tomomatsu K; Kitahara A; Takihara T; Niimi K; Oguma T; Asano K
    Tokai J Exp Clin Med; 2020 Dec; 45(4):224-229. PubMed ID: 33300594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of ST2 in helper T lymphocytes of malignant pleural effusions.
    Oshikawa K; Yanagisawa K; Ohno S; Tominaga S; Sugiyama Y
    Am J Respir Crit Care Med; 2002 Apr; 165(7):1005-9. PubMed ID: 11934729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion.
    Yeh HH; Lai WW; Chen HH; Liu HS; Su WC
    Oncogene; 2006 Jul; 25(31):4300-9. PubMed ID: 16518408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.
    Du N; Li X; Li F; Zhao H; Fan Z; Ma J; Fu Y; Kang H
    Oncol Rep; 2013 Jun; 29(6):2332-40. PubMed ID: 23525453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion.
    Wang D; Yang L; Yue D; Cao L; Li L; Wang D; Ping Y; Shen Z; Zheng Y; Wang L; Zhang Y
    Cancer Lett; 2019 Jun; 452():244-253. PubMed ID: 30928379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor level correlates with transforming growth factor-beta isoform levels in pleural effusions.
    Cheng D; Lee YC; Rogers JT; Perkett EA; Moyers JP; Rodriguez RM; Light RW
    Chest; 2000 Dec; 118(6):1747-53. PubMed ID: 11115468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of interleukine-6, transforming growth factor-beta 1 and vascular endothelial growth factor in malignant pleural effusions.
    Duysinx BC; Corhay JL; Hubin L; Nguyen D; Henket M; Louis R
    Respir Med; 2008 Dec; 102(12):1708-14. PubMed ID: 18760578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.